vs
艺达思集团（IEX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是艺达思集团的1.9倍（$772.1M vs $398.4M），艺达思集团净利率更高（30.1% vs 12.7%，领先17.4%），艺达思集团同比增速更快（16.7% vs 5.9%），Revvity自由现金流更多（$161.8M vs $86.0M），过去两年Revvity的营收复合增速更高（9.0% vs -29.4%）
艺达思集团是一家公开上市的工业制造企业，专注于流体系统与特种工程产品的研发和生产，产品广泛应用于工业制造、生命科学、食品安全等多个领域，可为全球各行业客户提供高性能定制化解决方案。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
IEX vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$398.4M
营收增速更快
IEX
高出10.8%
5.9%
净利率更高
IEX
高出17.4%
12.7%
自由现金流更多
RVTY
多$75.8M
$86.0M
两年增速更快
RVTY
近两年复合增速
-29.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $398.4M | $772.1M |
| 净利润 | $120.0M | $98.4M |
| 毛利率 | 99.9% | — |
| 营业利润率 | 43.3% | 14.5% |
| 净利率 | 30.1% | 12.7% |
| 营收同比 | 16.7% | 5.9% |
| 净利润同比 | 25.7% | 3.9% |
| 每股收益（稀释后） | $1.61 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IEXRVTY
| Q2 26 | $398.4M | — | ||
| Q1 26 | $407.7M | — | ||
| Q4 25 | $899.1M | $772.1M | ||
| Q3 25 | $878.7M | $698.9M | ||
| Q2 25 | $865.4M | $720.3M | ||
| Q1 25 | $814.3M | $664.8M | ||
| Q4 24 | $862.9M | $729.4M | ||
| Q3 24 | $798.2M | $684.0M |
净利润IEXRVTY
| Q2 26 | $120.0M | — | ||
| Q1 26 | $128.3M | — | ||
| Q4 25 | $128.3M | $98.4M | ||
| Q3 25 | $127.8M | $46.7M | ||
| Q2 25 | $131.6M | $53.9M | ||
| Q1 25 | $95.5M | $42.2M | ||
| Q4 24 | $123.2M | $94.6M | ||
| Q3 24 | $119.1M | $94.4M |
毛利率IEXRVTY
| Q2 26 | 99.9% | — | ||
| Q1 26 | 94.9% | — | ||
| Q4 25 | 43.1% | — | ||
| Q3 25 | 44.5% | 53.6% | ||
| Q2 25 | 45.3% | 54.5% | ||
| Q1 25 | 45.3% | 56.5% | ||
| Q4 24 | 42.5% | — | ||
| Q3 24 | 44.3% | 56.3% |
营业利润率IEXRVTY
| Q2 26 | 43.3% | — | ||
| Q1 26 | 45.0% | — | ||
| Q4 25 | 20.4% | 14.5% | ||
| Q3 25 | 21.1% | 11.7% | ||
| Q2 25 | 21.7% | 12.6% | ||
| Q1 25 | 17.4% | 10.9% | ||
| Q4 24 | 19.2% | 16.3% | ||
| Q3 24 | 21.0% | 14.3% |
净利率IEXRVTY
| Q2 26 | 30.1% | — | ||
| Q1 26 | 31.5% | — | ||
| Q4 25 | 14.3% | 12.7% | ||
| Q3 25 | 14.5% | 6.7% | ||
| Q2 25 | 15.2% | 7.5% | ||
| Q1 25 | 11.7% | 6.4% | ||
| Q4 24 | 14.3% | 13.0% | ||
| Q3 24 | 14.9% | 13.8% |
每股收益（稀释后）IEXRVTY
| Q2 26 | $1.61 | — | ||
| Q1 26 | $1.71 | — | ||
| Q4 25 | $1.71 | $0.86 | ||
| Q3 25 | $1.70 | $0.40 | ||
| Q2 25 | $1.74 | $0.46 | ||
| Q1 25 | $1.26 | $0.35 | ||
| Q4 24 | $1.61 | $0.77 | ||
| Q3 24 | $1.57 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $586.2M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.0B | $7.3B |
| 总资产 | $6.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资IEXRVTY
| Q2 26 | $586.2M | — | ||
| Q1 26 | $580.0M | — | ||
| Q4 25 | $580.0M | $919.9M | ||
| Q3 25 | $593.8M | $931.4M | ||
| Q2 25 | $568.2M | $991.8M | ||
| Q1 25 | $594.1M | $1.1B | ||
| Q4 24 | $620.8M | $1.2B | ||
| Q3 24 | $633.2M | $1.2B |
总债务IEXRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | — | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.1B | — |
股东权益IEXRVTY
| Q2 26 | $4.0B | — | ||
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $7.3B | ||
| Q3 25 | $4.0B | $7.4B | ||
| Q2 25 | $4.0B | $7.6B | ||
| Q1 25 | $3.9B | $7.6B | ||
| Q4 24 | $3.8B | $7.7B | ||
| Q3 24 | $3.8B | $7.9B |
总资产IEXRVTY
| Q2 26 | $6.9B | — | ||
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.9B | $12.2B | ||
| Q3 25 | $7.0B | $12.1B | ||
| Q2 25 | $6.9B | $12.4B | ||
| Q1 25 | $6.8B | $12.4B | ||
| Q4 24 | $6.7B | $12.4B | ||
| Q3 24 | $7.0B | $12.8B |
负债/权益比IEXRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.55× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $86.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 21.6% | 21.0% |
| 资本支出强度资本支出/营收 | 4.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $654.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流IEXRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $209.5M | $182.0M | ||
| Q3 25 | $203.5M | $138.5M | ||
| Q2 25 | $161.7M | $134.3M | ||
| Q1 25 | $105.7M | $128.2M | ||
| Q4 24 | $172.6M | $174.2M | ||
| Q3 24 | $205.3M | $147.9M |
自由现金流IEXRVTY
| Q2 26 | $86.0M | — | ||
| Q1 26 | $189.8M | — | ||
| Q4 25 | $189.8M | $161.8M | ||
| Q3 25 | $188.7M | $120.0M | ||
| Q2 25 | $146.9M | $115.5M | ||
| Q1 25 | $91.4M | $112.2M | ||
| Q4 24 | $157.1M | $149.8M | ||
| Q3 24 | $191.6M | $125.6M |
自由现金流率IEXRVTY
| Q2 26 | 21.6% | — | ||
| Q1 26 | 46.6% | — | ||
| Q4 25 | 21.1% | 21.0% | ||
| Q3 25 | 21.5% | 17.2% | ||
| Q2 25 | 17.0% | 16.0% | ||
| Q1 25 | 11.2% | 16.9% | ||
| Q4 24 | 18.2% | 20.5% | ||
| Q3 24 | 24.0% | 18.4% |
资本支出强度IEXRVTY
| Q2 26 | 4.4% | — | ||
| Q1 26 | 15.6% | — | ||
| Q4 25 | 2.2% | 2.6% | ||
| Q3 25 | 1.7% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 1.8% | 3.4% | ||
| Q3 24 | 1.7% | 3.3% |
现金转化率IEXRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.63× | 1.85× | ||
| Q3 25 | 1.59× | 2.97× | ||
| Q2 25 | 1.23× | 2.49× | ||
| Q1 25 | 1.11× | 3.03× | ||
| Q4 24 | 1.40× | 1.84× | ||
| Q3 24 | 1.72× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IEX
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
